Evidence map›Paper›PMID 31677389›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2020

The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.

Zhila Semnani-Azad, Philip W Connelly, Luke W Johnston, Ravi Retnakaran, Stewart B Harris, Bernard Zinman, Anthony J Hanley

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Triglycerides, Glucose Metabolism, and Type 2 Diabetes.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Zhila Semnani-AzadDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.
Philip W ConnellyKeenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Canada.
Luke W JohnstonDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Ravi RetnakaranDivision of Endocrinology and Metabolism, University of Toronto, Toronto, Canada.
Stewart B HarrisDepartment of Family Medicine, Western University, London, Canada.
Bernard ZinmanDivision of Endocrinology and Metabolism, University of Toronto, Toronto, Canada.
Anthony J HanleyDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada.
Mount Sinai Hospital · CAAarhus University · DKSt. Michael's Hospital · CAUniversity of Toronto · CAWestern University · CA

Funding

CIHR
6 · The paper itself

Abstract

contextChronic inflammation arising from adipose tissue macrophage (ATM) activation may be central in type 2 diabetes etiology. Our objective was to assess the longitudinal associations of soluble CD163 (sCD163), a novel biomarker of ATM activation, with insulin sensitivity, β-cell function, and dysglycemia in high-risk subjects.

methodsAdults at risk for type 2 diabetes in the Prospective Metabolism and Islet Cell Evaluation (PROMISE) study had 3 assessments over 6 years (n = 408). Levels of sCD163 were measured using fasting serum. Insulin sensitivity was assessed by HOMA2-%S and the Matsuda index (ISI). β-cell function was determined by insulinogenic index (IGI) over HOMA-IR and insulin secretion-sensitivity index-2 (ISSI-2). Incident dysglycemia was defined as the onset of impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes. Generalized estimating equations (GEE) evaluated longitudinal associations of sCD163 with insulin sensitivity, β-cell function, and incident dysglycemia adjusting for demographic and lifestyle covariates. Areas under receiver-operating-characteristic curve (AROC) tested whether sCD163 improved dysglycemia prediction in a clinical model.

resultsLongitudinal analyses showed significant inverse associations between sCD163 and insulin sensitivity (% difference per standard deviation increase of sCD163 for HOMA2-%S (β = -7.01; 95% CI, -12.26 to -1.44) and ISI (β = -7.60; 95% CI, -11.09 to -3.97) and β-cell function (ISSI-2 (β = -4.67; 95 %CI, -8.59 to -0.58) and IGI/HOMA-IR (β = -8.75; 95% CI, -15.42 to -1.56)). Increased sCD163 was associated with greater risk for incident dysglycemia (odds ratio = 1.04; 95% CI, 1.02-1.06; P < 0.001). Adding sCD163 data to a model with clinical variables improved prediction of incident dysglycemia (AROC=0.6731 vs 0.638; P < 0.05).

conclusionssCD163 was longitudinally associated with core disorders that precede the onset of type 2 diabetes.

Indexed as

Macrophage ActivationAdipose TissueAdultAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersBlood GlucoseCD163 AntigenDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansInsulin ResistanceIslets of LangerhansLongitudinal StudiesMacrophagesAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersBlood GlucoseCD163 AntigenReceptors, Cell Surface

Identifiers

PMID31677389
PMCPMC7112970
OpenAlexW2986190542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.